25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Patent number: 8765910Abstract: The invention relates to a method for producing C-terminal amidated dibasic or polybasic peptides, consisting in reacting two peptides in the presence of trypsin biologically active enzymes and, if necessary, in purifying the thus obtainable compounds of formula (I) by means of protein chemistry.Type: GrantFiled: September 13, 2006Date of Patent: July 1, 2014Assignee: Sanofi-Aventis Deutschland GmbHInventors: Sebastian Rissom, Paul Habermann, Christophe Salagnad, Frank Zocher, Laure Landric-Burtin
-
Patent number: 8765908Abstract: The present invention provides a therapeutic composition, and method of use thereof, for improving bone mass, rigidity, or strength, or preventing and treating bone loss via modulation of the RANK signaling pathway. The therapeutic composition of the present invention comprises a RYBP peptide, or fragments thereof, that specifically interact with a motif of RANK to regulate osteoclastogenesis. The present invention further provides a composition, and method of use thereof, comprising a modulator that is capable of modulating the RYBP-RANK interaction, or modulating an effector in the RANK signaling pathway through the RYBP-RANK interaction.Type: GrantFiled: August 10, 2012Date of Patent: July 1, 2014Assignee: The UAB Research FoundationInventors: Xu Feng, Shunqing Wang
-
Patent number: 8765688Abstract: The present invention relates to the use of special peptides in composition which can be used in particular in hair and skin cosmetics, and to such peptide-containing compositions. In particular, the present invention relates to the use of such peptides as active ingredient for inhibition or treatment of dandruff which does not accumulate in the body or in the environment. Furthermore, the invention relates to the production of such compositions, to the peptides used themselves, to their production and to coding nucleotide sequences for such peptides, to dispensing systems for such peptides and to screening methods for identifying suitable further peptides.Type: GrantFiled: December 19, 2008Date of Patent: July 1, 2014Assignee: BASF SEInventors: Burghard Liebmann, Heike Brüser, Heiko Barg, Daniel Hümmerich, Hubertus Peter Bell
-
Publication number: 20140179593Abstract: Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dnc1, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl).Type: ApplicationFiled: May 16, 2012Publication date: June 26, 2014Applicant: St. Jude Children's Research HospitalInventors: Julie K. Monda, Brenda A. Schulman, Daniel C. Scott
-
Publication number: 20140178855Abstract: Novel murine astroviruses, and methods of detecting the viruses are disclosed. Also disclosed are uses of the viruses and infected animals as model systems for discovery and development of vaccines and therapies for diseases caused by or associated with astrovirus infection, including human astrovirus-based diseases.Type: ApplicationFiled: August 1, 2013Publication date: June 26, 2014Applicant: WASHINGTON UNIVERSITYInventors: Herbert W. Virgin, David Wang, Joy Loh, Thad Stappenbeck, Guoyan Zhao, Larissa Thackray, Christine Yokoyama
-
Publication number: 20140179899Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: Chem. 1, Chem. 2, Chem. 3 or Chem. 4; or a pharmaceutically acceptable salt, amide, or ester thereof.Type: ApplicationFiled: December 10, 2013Publication date: June 26, 2014Applicant: NOVO NORDISK A/SInventors: Patrick William Garibay, Jane Spetzler, Janos Tibor Kodra, Lars Linderoth, Jesper Lau, Per Sauerberg
-
Publication number: 20140179595Abstract: Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication.Type: ApplicationFiled: July 20, 2012Publication date: June 26, 2014Applicants: UNIVERSITY OF SOUTH CAROLINA, University of Pittsburgh- Of the Commonwealth System of Higher EducationInventors: Tianyi Wang, Shufeng Liu, Fan Daping
-
Publication number: 20140179898Abstract: A modified protein of an extracellular domain of protein A, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein A, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein A bound with the Fc region of immunoglobulin G, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the Fc region and have a 20% or more ratio of exposed surface area, by histidine residues. Preferably, the modified protein is obtained by the substitution of amino acid residues at sites identified from the analysis of sequences selected from a library constituted by the protein group, by histidine residues. These substitutions may be combined.Type: ApplicationFiled: December 3, 2013Publication date: June 26, 2014Applicant: NAT'L INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Shinya Honda, Hideki Watanabe, Masayuki Tsukamoto
-
Publication number: 20140179614Abstract: The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: ApplicationFiled: November 21, 2013Publication date: June 26, 2014Applicant: University of TasmaniaInventors: Vladimir Berezin, Elisabeth Bock, Milena Penkowa
-
Publication number: 20140178990Abstract: A method for manufacturing at least one kind of eukaryotic cells or a biosynthetic substance derived from the eukaryotic cells by proliferating the cells, which includes preparing an artificially synthesized peptide for promoting proliferation of the at least one kind of eukaryotic cells, incubating the eukaryotic cells in a culture medium, and adding the synthesized peptide at least once to the culture medium during the incubation process. The synthesized peptide includes an amino acid sequence selected from SEQ ID NOS: 1 to 18, and an amino acid sequence selected from SEQ ID NOS: 19 to 97.Type: ApplicationFiled: January 24, 2014Publication date: June 26, 2014Applicants: JAPAN TISSUE ENGINEERING CO., LTD., TOAGOSEI CO. LTD.Inventors: Tetsuhiko YOSHIDA, Nahoko KOBAYASHI, Mikio NIWA, Chikara SHINOHARA, Masatoki WATANABE, Ken-ichiro HATA
-
Patent number: 8759295Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: GrantFiled: May 21, 2010Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
-
Patent number: 8759480Abstract: According to the present invention, there is provided a range of new conotoxin derivatives and methods for synthesizing these analogues and other intramolecular dicarba bridge-containing peptides, including dicarba-disulfide bridge-containing peptides.Type: GrantFiled: February 16, 2012Date of Patent: June 24, 2014Assignee: Syngene LimitedInventors: Andrea Robinson, Jomana Elaridi
-
Patent number: 8759290Abstract: The present invention relates to the field of metabolic compound conjugates, methods of forming said conjugates and uses of these conjugates in the treatment of diabetes and conditions related to this condition. The metabolic compound conjugates of this invention include a metabolic peptide having a glucagon-like peptide (GLP-1) receptor binding motif for action on a GLP-1 receptor and at least one oligomer conjugation site for binding with at least one oligomer, wherein the oligomer includes a polyethylene glycol moiety (PEG), and/or alkyl moiety.Type: GrantFiled: October 18, 2006Date of Patent: June 24, 2014Assignee: Biocon LimitedInventor: Kenneth D. James
-
Patent number: 8759299Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.Type: GrantFiled: July 22, 2010Date of Patent: June 24, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Nicholas C. Prairie, Maria L. Ufret, Jundong Zhang, Deborah M. Rothman, Jeanne Mary Comstock
-
Publication number: 20140170179Abstract: Described are particular fragments of the cyclin-dependent kinase inhibitor p16 capable of increasing IFN-? secretion of T cells or inducing proliferation of T cells and the use of said fragments for immunizing an individual against HPV-associated or other p16INK4a expressing carcinomas, preferably advanced carcinomas.Type: ApplicationFiled: December 13, 2012Publication date: June 19, 2014Applicant: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Matthias KLOOR, Miriam REUSCHENBACH, Magnus VON KNEBEL-DOEBERITZ
-
Publication number: 20140170683Abstract: The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.Type: ApplicationFiled: July 26, 2013Publication date: June 19, 2014Applicant: NESTEC S.A.Inventors: Nicholas Chi-Kwan Ling, Shui Long Wang, Dunrui Wang, Sharat Singh
-
Publication number: 20140170124Abstract: The present disclosure provides a modified cecropin protein comprising a cecropin or a variant thereof fused to a hydrophilic tail lacking a C-terminal glycine. The present disclosure also provides pharmaceutical compositions, methods and uses of the modified cecropin protein or nucleic acid for treating or preventing endoparasites, such as Plasmodium, and bacteria.Type: ApplicationFiled: July 13, 2012Publication date: June 19, 2014Applicant: SOLARVEST BIOENERGY INC.Inventors: Subrata Chowdhury, Michael Thomas Horne
-
Publication number: 20140171375Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.Type: ApplicationFiled: June 6, 2012Publication date: June 19, 2014Applicant: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Patent number: 8754042Abstract: The present invention relates to novel agents, pharmaceutical compositions containing them, and their use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO:40 which have surprisingly been shown to have inhibitory effects on the growth and/or viability of cells, particularly bacterial and cancer cells. Also provided are therapeutic and non-therapeutic methods which comprise the use of peptides of the invention.Type: GrantFiled: February 1, 2011Date of Patent: June 17, 2014Assignee: Cytovation ASInventor: Lars Prestegarden
-
Patent number: 8753639Abstract: This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof.Type: GrantFiled: March 31, 2010Date of Patent: June 17, 2014Assignees: University of Washington through its Center for Commercialization, Compliment CorporationInventors: André Lieber, Hongjie Wang, Ronald Jay Berenson, Darrick Carter
-
Patent number: 8754047Abstract: The present invention provides isolated peptides with at least two cysteine residues capable of forming one or more disulfide bonds. Pharmaceutical compositions comprising the isolated peptides of the present invention are also provided. The invention also provides methods for inhibiting, preventing or improving the pathological or clinical manifestations of cancer or an inflammatory disease or disorder in a subject, comprising administering a peptide of the invention.Type: GrantFiled: January 27, 2011Date of Patent: June 17, 2014Assignee: The Research Foundation for the State University of New YorkInventors: Basil Rigas, Yu Sun
-
Patent number: 8754051Abstract: The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1Fo ATP synthase (dF1Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major focus of the patent protection will be 2 peptides comprising an amino acid sequence having at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 and pharmaceutical compositions thereof. However, additional peptide sequences within the dF1Fo protein may also have efficacies in these disease states and therefore all peptides shown in the Figures of this application (combined with the human immunodeficiency virus (HIV)-Tat protein transduction, cytochrome oxidase subunit IV (COIV) mitochondrial targeting and Flag domains) are included for their efficacies in these conditions.Type: GrantFiled: February 21, 2012Date of Patent: June 17, 2014Assignee: Georgia Regents Research Institute, Inc.Inventors: John A. Johnson, Tiffany Tuyen M. Nguyen, Mourad Ogbi
-
Publication number: 20140162938Abstract: Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.Type: ApplicationFiled: December 3, 2013Publication date: June 12, 2014Applicant: The Board of Regents of the University of OklahomaInventor: Heloise Anne Pereira
-
Publication number: 20140162945Abstract: The present invention provides a GIP analog, which is derived from GIP (1-29, SEQ ID NO: 1), has both GLP-1 agonist activity and GIPR stimulation activity, and comprises an amino acid sequence represented by the following formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu-A27-A28-A29-Y. The present invention also provides a pharmaceutical composition comprising the GIP analog and use thereof.Type: ApplicationFiled: June 8, 2012Publication date: June 12, 2014Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Tao Ma, Shusen Xu, Zhijun Liu, Bo Zhang, Ning Shen, Hai Yang, Wei Zhang, Yuhua Li, Sunghwan Moon, Maengsup Kim
-
Publication number: 20140163201Abstract: The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions.Type: ApplicationFiled: November 26, 2013Publication date: June 12, 2014Applicant: BICYCLE THERAPEUTICS LIMITEDInventors: Gregory Paul Winter, Christian Heinis, Elise Bernard, David Loakes, John Tite, Marina Vaysburd, Daniel Paul Teufel, Lutz Riechmann
-
Publication number: 20140162296Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.Type: ApplicationFiled: March 14, 2013Publication date: June 12, 2014Inventors: Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
-
Publication number: 20140165222Abstract: The potential use of these “SUMO receptors” to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.Type: ApplicationFiled: March 8, 2012Publication date: June 12, 2014Applicant: ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNEInventor: Manuel Salvador Rodriguez Medina
-
Publication number: 20140162936Abstract: The present invention relates to a polypeptide binding to a chymase (EC 3, 4, 21,39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X1)A(X2)(X3)(X4)(X5) (X6)LSFHKGEKFQIL(X7 (X8)(X9)(X10) (X11)(X12)G(X13)(X14)WEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X1) is R, N, Q, E, K, H, S, T, C, or D; (X2) is E, T, D, Q, L, P, A, S, C, M, N, E, G, A, V or I; (X3) is R, T, H, N, K, S, C, N or Q; (X4) is S, W, T, C, N, Q, For Y; (X5) is T, H, L, F, C, S, M, N, Q, R, K, G, A, V, I, P, Y or W; (X6) is D, Q, H, E, S, T, C, N, R or K; (X7) is D, N, R, E, Q, S, T, C, K or D; (X8) is M, W, G, F, A, S, T, C, S, N, Q, Y, V, L, I or P; (X9) is T, H, S, D, C, N, Q, R, K, E or absent; (X10) is V, T, Q, G, A, L, I, P, S, C, M, N or absent; (X11) is P, A, D, G, K, V, L, I, E, R, M, H or absent; (X12) is N, V, P, I, E, T, S, A, G, L, C, M, Q or D; (X13) is D, E, T, P, G, A, V, L, I, S, C, M, N or Q, and (X14) is W, Y, L, G, A, V, I, P, M, or F; (b)Type: ApplicationFiled: April 24, 2012Publication date: June 12, 2014Applicant: COVAGEN AGInventors: Simon Brack, Sarah Batey, Dragan Grabulovski, Julian Bertschinger, Daniel Schlatter, Jörg Benz, David Banner, Michael Hennig
-
Publication number: 20140162961Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.Type: ApplicationFiled: December 9, 2013Publication date: June 12, 2014Applicant: OPHIDION INC.Inventor: Andreas Walz
-
Publication number: 20140162956Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.Type: ApplicationFiled: July 8, 2011Publication date: June 12, 2014Inventors: Caroline Ekblad, Lars Abrahmsen
-
Publication number: 20140162960Abstract: Aspects of the invention include compositions and methods for inhibiting the interaction between scaffold proteins and kinases. These compositions and methods find a number of uses including, for example, suppressing tumor growth and metastasis and reducing tumor size and number in a mammal with cancer.Type: ApplicationFiled: April 5, 2012Publication date: June 12, 2014Applicant: The Board of Trustees of the Leland Stanford Junior universityInventors: Katherine LaRoque Jameson, Paul A. Khavari
-
Patent number: 8748170Abstract: In one embodiment, the invention provides a composition comprising one or more polypeptide(s), each of said polypeptide(s) comprising a sequence selected from the group consisting of KFRLLQETMYMTVSI (SEQ ID NO: 1), LQETMYMTVSIIDRF (SEQ ID NO: 2), and MYMTVSIIDRFM (SEQ ID NO: 3), or a combination of two or three such polypeptides, wherein each of said polypeptide(s) consist(s) of at most 24 amino acid residues, the composition also comprising a carrier. In another embodiment, the invention provides a composition comprising one or more bacterial or viral vectors comprising one or more nucleic acid molecule(s) encoding one or more polypeptide(s), each of said polypeptide(s) having a sequence selected from the group consisting of KFRLLQETMYMTVSI (SEQ ID NO: 1), LQETMYMTVSIIDRF (SEQ ID NO: 2), and MYMTVSIIDRFM (SEQ ID NO: 3), wherein each of said polypeptide(s) consist(s) of at most 24 amino acid residues.Type: GrantFiled: July 27, 2009Date of Patent: June 10, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Olivera J. Finn, Laura A. Vella-Geynisman
-
Patent number: 8748373Abstract: A polypeptide comprising a preS1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the preS2 region of HBV or a fragment thereof, and methods of use to inhibit virus infection are disclosed. A lentivirus comprising hepatitis B virus (HBV) envelope proteins, or a fragment thereof, and/or the L envelope protein of HBV and/or the M envelope protein of HBV or a fragment thereof, and/or the S envelope protein of HBV or a fragment thereof, and methods of use of this lentivirus HBV pseudovirus as a gene therapy to target hepatocytes for the administration of therapeutic agents are also disclosed.Type: GrantFiled: February 20, 2008Date of Patent: June 10, 2014Assignee: Fox Chase Cancer CenterInventors: Ning Chai, John M. Taylor
-
Patent number: 8748571Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: October 20, 2011Date of Patent: June 10, 2014Assignee: Amgen Inc.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 8748393Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on dynamin 1-like protein (Drp1) guanosine triphosphate phosphatase (GTPase) activity, binding of Drp1 to mitochondrial fission 1 protein (Fis1), reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.Type: GrantFiled: May 14, 2012Date of Patent: June 10, 2014Assignee: The Board of Trustees of The Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
-
Patent number: 8748394Abstract: A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a synthetic apolipoprotein A-1 (Apo A-I) mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including a synthetic apolipoprotein A-I (Apo A-I) mimetic peptide, or combination of an Apo A-I synthetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of an endogenous Apo A-I related peptide. A composition including an apolipoprotein A-1 (Apo A-I) synthetic peptide in a form suitable for delivery into a blood vessel, the peptide including an amino acid backbone that has less amino acid residues relative to endogenous Apo A-I and a chimera of helix 1 and helix 9 of Apo A-I.Type: GrantFiled: February 22, 2013Date of Patent: June 10, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: Katsuyuki Murase, Li Zhao, Irina Astafieva, Paul M. Consigny
-
Patent number: 8748386Abstract: The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.Type: GrantFiled: June 10, 2010Date of Patent: June 10, 2014Assignee: New York UniversityInventor: Einar M. Sigurdsson
-
Patent number: 8747808Abstract: A radiolabeled annexin comprising at least 2 up to 20 histidine residues at its N-terminus is disclosed. At least two of said histidine residues are adjacent or separated by no more than one other amino acid. The radiolabeled annexin is a stable complex with a radionuclide such as technetium 99m. The radiolabeled annexin can be used in a method of imaging cell death in a nucleated cell within a region of a mammalian subject in vivo.Type: GrantFiled: August 26, 2009Date of Patent: June 10, 2014Assignee: MosaMedix B.V.Inventors: Christiaan Peter Maria Reutelingsperger, Peter Jozef Jacobus Moonen
-
Patent number: 8748395Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are described.Type: GrantFiled: September 12, 2006Date of Patent: June 10, 2014Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 8748389Abstract: The present invention provides a peptide comprising an amino acid sequence that is part of the amino acid sequence of CDK4 protein, or homologous to part of the amino acid sequence of CDK4 protein, which peptide is cytotoxic to, and/or inhibiting to the growth of, a cancer cell and/or stimulating to the growth of a non-cancerous cell and/or a control cell. Methods of identifying such peptides and medical uses of such peptides are also disclosed.Type: GrantFiled: June 14, 2005Date of Patent: June 10, 2014Assignee: Theryte LimitedInventors: Hilmar Meek Warenius, Jonathan Essex, Jeremy Kilburn
-
Patent number: 8748368Abstract: The invention relates to a method for preserving an organ or tissue comprising contacting the organ or tissue with an effective amount of a kallikrein inhibitor and solutions useful for such a method. Also provided is a method for reducing reperfusion injury of an organ during surgery and/or following removal of the organ from a subject comprising placing the organ in an organ storage and preservative solution, wherein the solution comprises a kallikrein inhibitor.Type: GrantFiled: March 19, 2010Date of Patent: June 10, 2014Assignee: DYAX Corp.Inventors: Marco Cicardi, Luigi Bergamaschini
-
Publication number: 20140155318Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.Type: ApplicationFiled: September 3, 2013Publication date: June 5, 2014Applicant: Tel Hashomer Medical Research, Infrastructure and Services Ltd.Inventor: Amir ZLOTKIN
-
Publication number: 20140154279Abstract: Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided.Type: ApplicationFiled: December 28, 2011Publication date: June 5, 2014Applicant: CellAct Pharma GmbHInventor: Nalân UTKU
-
Publication number: 20140155329Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: ApplicationFiled: April 5, 2012Publication date: June 5, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Chia Lin Chang
-
Publication number: 20140155314Abstract: Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.Type: ApplicationFiled: June 13, 2012Publication date: June 5, 2014Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Yulia A. Komarova, Uzma Saqib, Stephen M. Vogel, Asrar B. Malik
-
Publication number: 20140154282Abstract: Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in a platform in order to form a two-stranded antigen suitable for immunization of a subject.Type: ApplicationFiled: January 26, 2012Publication date: June 5, 2014Inventors: Robert S. Hodges, Kathryn V. Holmes, Zhe Yan, Wendy Jeanne Hartsock, Zhaohui Qian, Brooke Elizabeth Bishop Hirsch
-
Publication number: 20140155324Abstract: The invention relates to polypeptides exhibiting metabolic-modulating as well as immunomodulatory properties, nucleic acids encoding them, compositions comprising them, and methods of treating metabolic disorders and/or immune-related disorders comprising their administration and to their use in preparing pharmaceutical compositions for the treatment, amelioration, prophylaxis or delaying the onset of at least one of a metabolic disorder and an immune-related disorder.Type: ApplicationFiled: August 6, 2012Publication date: June 5, 2014Applicant: TWO TO BIOTECH LTD.Inventors: Tamara Sandler, Orly Devary
-
Publication number: 20140154812Abstract: A real-time portable and rapid detection assay to identify the presence of biologically active toxins such as botulinum toxins. The proteolytic activity of BoNT/A is measured using a peptide cleavage assay, where a fluorescent substrate is cleaved by BoNT/A, resulting in increased fluorescence. This fluorescence can be monitored in real-time using a fluorescence detection instrument, such as a real-time PCR system that has been modified to implement a detection algorithm specific to the identification of the target toxin.Type: ApplicationFiled: March 15, 2013Publication date: June 5, 2014Inventors: Kenton Arthur Doctor, Stacey Ann Massulik, Frances Louise Stites, Timothy Francis Moshier, Jeffrey Harold Mills, Lisa Helen Chamberlin, Deborah L. Plochocki, Olivia Jennifer Barrett, Huda Sirageldin Suliman
-
Publication number: 20140155317Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.Type: ApplicationFiled: February 11, 2014Publication date: June 5, 2014Applicants: C3 JIAN, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Maxwell H. Anderson, Fengxia Qi, Jian He, Ian H. McHardy
-
Publication number: 20140155321Abstract: The present invention relates to a polypeptide or a product comprising said polypeptide for use in the treatment and/or prevention of a fungal infection caused by Malassezia spp. and/or a Malassezia spp associated condition wherein the polypeptide comprises a sequence of about 25 to 200 amino acids wherein substantially all of the amino acids in said sequence are lysine; pharmaceutical compositions comprising said polypeptide or product and uses thereof.Type: ApplicationFiled: March 14, 2013Publication date: June 5, 2014Applicant: Novabiotics LimitedInventors: Deborah O'NEIL, Derry MERCER, Colin STEWART